

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Recce Pharmaceuticals Ltd (Company)
ABN	73 124 849 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr John Prendergast
Date of last notice	21 November 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (j) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	16 May 2025
No. of securities held prior to change	306,819 fully paid ordinary shares 2,175,000 unlisted options each exercisable at \$1.56, expiring 22 February 2026 2,650,000 unlisted options each exercisable at \$0.80, expiring 14 November 2029
Class	Fully paid ordinary shares
Number acquired	51,136 fully paid ordinary shares
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$0.28 (28 cents) per fully paid ordinary share

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	357,955 fully paid ordinary shares 2,175,000 unlisted options each exercisable at \$1.56, expiring 22 February 2026 2,650,000 unlisted options each exercisable at \$0.80, expiring 14 November 2029
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Participation in the Company's pro-rata non renounceable entitlement offer as announced by the Company on 10 April 2025.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
--	-----

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

For personal use only

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Recce Pharmaceuticals Ltd (Company)
ABN	73 124 849 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	James Graham
Date of last notice	21 November 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (j) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and indirect interest
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Mr. James Graham is the trustee of the J Graham Family Trust and a beneficiary of the trust Buttonwood Nominees Pty Ltd held on behalf of Mr James Graham
Date of change	16 May 2025
No. of securities held prior to change	<p>Direct Interest</p> <ol style="list-style-type: none"> 1. 389,712 Class B Performance Shares 2. 2,250,000 each exercisable at \$1.56, expiring 22 February 2026 3. 3,000,000 unlisted options each exercisable at \$0.80, expiring 14 November 2029 <p>Indirect Interest</p> <p>Mr. James Graham <J Graham Family A/c></p> <ol style="list-style-type: none"> 4. 356,250 Class B Performance Shares <p>Buttonwood Nominees Pty Ltd</p> <ol style="list-style-type: none"> 5. 6,765,362 fully paid ordinary shares
Class	Fully paid ordinary shares

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

Number acquired	35,714 fully paid ordinary shares
Number disposed	Nil
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$0.28 (28 cents) per fully paid ordinary share
No. of securities held after change	<p>Direct Interest</p> <ol style="list-style-type: none"> 1. 389,712 Class B Performance Shares 2. 2,250,000 each exercisable at \$1.56, expiring 22 February 2026 3. 3,000,000 unlisted options each exercisable at \$0.80, expiring 14 November 2029 <p>Indirect Interest</p> <p>Mr. James Graham <J Graham Family A/c></p> <ol style="list-style-type: none"> 4. 356,250 Class B Performance Shares <p>Buttonwood Nominees Pty Ltd</p> <ol style="list-style-type: none"> 5. 6,801,076 fully paid ordinary shares
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Participation in the Company's pro-rata non renounceable entitlement offer as announced by the Company on 10 April 2025.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Recce Pharmaceuticals Ltd (Company)
ABN	73 124 849 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Justin Ward
Date of last notice	21 November 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (j) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	16 May 2025
No. of securities held prior to change	301,444 fully paid ordinary shares 600,000 unlisted options each exercisable at \$1.56, expiring 22 February 2026 1,000,000 unlisted options each exercisable at \$0.80, expiring 14 November 2029
Class	Fully paid ordinary shares
Number acquired	50,240 fully paid ordinary shares
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$0.28 (28 cents) per fully paid ordinary share

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	351,684 fully paid ordinary shares 600,000 unlisted options each exercisable at \$1.56, expiring 22 February 2026 1,000,000 unlisted options each exercisable at \$0.80, expiring 14 November 2029
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Participation in the Company's pro-rata non renounceable entitlement offer as announced by the Company on 10 April 2025.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
--	-----

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

For personal use only

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Recce Pharmaceuticals Ltd (Company)
ABN	73 124 849 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Ms Michele Keryn Dilizia
Date of last notice	21 November 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (j) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	16 May 2025
No. of securities held prior to change	2,707,080 fully paid ordinary shares 577,212 Class B Performance Shares 1,500,000 unlisted options each exercisable at \$1.56, expiring 22 February 2026 1,600,000 unlisted options each exercisable at \$0.80, expiring 14 November 2029
Class	Fully paid ordinary shares
Number acquired	17,857 fully paid ordinary shares
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$0.28 (28 cents) per fully paid ordinary share

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	2,724,937 fully paid ordinary shares 577,212 Class B Performance Shares 1,500,000 unlisted options each exercisable at \$1.56, expiring 22 February 2026 1,600,000 unlisted options each exercisable at \$0.80, expiring 14 November 2029
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Participation in the Company's pro-rata non renounceable entitlement offer as announced by the Company on 10 April 2025.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

⁺ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

Were the interests in the securities or contracts detailed above traded during a ⁺ closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

For personal use only

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Recce Pharmaceuticals Ltd (Company)
ABN	73 124 849 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Alan Dunton
Date of last notice	21 November 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (j) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Danerius LLC an entity controlled by Dr Dunton
Date of change	16 May 2025
No. of securities held prior to change	126,819 fully paid ordinary shares 1,125,000 unlisted options each exercisable at \$1.56, expiring 22 February 2026 2,250,000 unlisted options each exercisable at \$0.80, expiring 14 November 2029
Class	Fully paid ordinary shares
Number acquired	19,469 fully paid ordinary shares
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$0.28 (28 cents) per fully paid ordinary share

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	146,288 fully paid ordinary shares 1,125,000 unlisted options each exercisable at \$1.56, expiring 22 February 2026 2,250,000 unlisted options each exercisable at \$0.80, expiring 14 November 2029
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Participation in the Company's pro-rata non renounceable entitlement offer as announced by the Company on 10 April 2025.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
--	-----

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

For personal use only

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Recce Pharmaceuticals Ltd (Company)
ABN	73 124 849 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Alistair McKeough
Date of last notice	21 November 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (j) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Finn Frist Pty Ltd as trustee for the AZM Superannuation Fund of which Mr McKeough is a director and shareholder of the trustee and a beneficiary of the trust (Finn Frist Pty Ltd) Amabel Pty Limited as trustee for the McKeough Family Trust of which Mr McKeough is a director of the trustee and a beneficiary of the trust (Amabel Pty Limited)
Date of change	16 May 2025
No. of securities held prior to change	Finn Frist Pty Ltd 1. 25,961 fully paid ordinary shares Amabel Pty Limited 2. 1,125,000 unlisted options each exercisable at \$1.56, expiring 15 November 2027 3. 1,000,000 unlisted options each exercisable at \$0.80, expiring 14 November 2029
Class	Fully paid ordinary shares
Number acquired	4,326 fully paid ordinary shares

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y Change of Director's Interest Notice

Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$0.28 (28 cents) per fully paid ordinary share
No. of securities held after change	Finn Frist Pty Ltd 1. 30,287 fully paid ordinary shares Amabel Pty Limited 2. 1,125,000 unlisted options each exercisable at \$1.56, expiring 15 November 2027 3. 1,000,000 unlisted options each exercisable at \$0.80, expiring 14 November 2029
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Participation in the Company's pro-rata non renounceable entitlement offer as announced by the Company on 10 April 2025.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A

+ See chapter 19 for defined terms.

For personal use only

Interest after change	N/A
-----------------------	-----

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

For personal use only